PolyPeptide Group AG (PPGN.SW) stock: key figures, P/E, revenue and dividend
Health Care · Switzerland · ISIN CH1110760852
PolyPeptide Group AG financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 338.69 m EUR | 391.28 m EUR |
| Gross profit | 36.00 m EUR | 63.80 m EUR |
| EBIT | -6.00 m EUR | 6.38 m EUR |
| Net income | -19.56 m EUR | -21.27 m EUR |
| Diluted EPS – continuing operations | -0.55 EUR | -0.65 EUR |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
More stocks
- Mayora Indah Tbk (MYOR.JK)
- SL Corp (005850.KS)
- Athens Water Supply and Sewerage Company SA (EYDAP.AT)
- JiangXi Tianxin Pharm Co Ltd (603235.SS)
- Draegerwerk AG & Co KGaA (DRW8.DE)
- Sanoma Oyj (SANOMA.HE)
- Alvotech (ALVO)
- Medartis Holding AG (MED.SW)
- Moltiply Group SpA (MOL.MI)
- Edinburgh Investment Trust PLC (EDIN.L)
- Frontier Group Holdings, Inc. (ULCC)
- TheRealReal, Inc. (REAL)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.